drugset
drugset / Trial / NCT03026803

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

NCT03026803 ↗

Phase 2 Terminated 4 enrolled City of Hope Medical Center Sanofi · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.

Timeline

Start
2006-11
Primary completion
2014-10
Completion
2014-10

Outcome

Outcome not reported

Stopped: “Due to Sorafenib became first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue to support”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 750 mg/m2 Oral
Subject Oxaliplatin Small molecule 50 mg/m2 Intravenous

Indications

hepatocellular carcinoma